SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bajaj Healthcare to resume commercial production of Citicoline Sodium

11 May 2022 Evaluate

Bajaj Healthcare (BHL) is all set to start commercial production of Citicoline Sodium, at the plant located at Panoli, Gujarat. The plant was involved in a fire incident last year and is now ready to commence operations at upgraded capacities. Citicoline Sodium is used to help memory loss due to aging, improve vision in people with glaucoma, and also helps with recovery in stroke patients & is administered as an injection or taken orally.

The plant will commence operations with an upgraded capacity of almost 2X of its previous installed capacity, not only in terms of the API but also its required intermediate as well. Equipped with the latest technology & increased efficiencies, the company will now also produce the Intermediate required for the product at the Panoli plant itself, which was previously being sourced from a different facility under BHL’s management. BHL plans to cater to the expanding demand of the product with a positive impact on its margins owing to better realization margins on the product. The plant at Panoli has been upgraded as per the latest technology confirming to the Good Manufacturing Practices (GMP) standards issued by NSF International, which are at par to international standards for pharmaceutical manufacturing

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.

Bajaj Healthcare Share Price

348.95 -1.50 (-0.43%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×